SKP2 and cancer: In addition, Aurora A kinase inhibitor LY3295668 [16], Aurora B kinase inhibitor AZD2811 [17], the mitotic inhibitors Taxol and STLC [18], and a SKP2 inhibitor [13] were all shown to be more selective against RB1-deficient cancer cells.